About FibroBiologics
FibroBiologics, Inc., a clinical-stage biotechnology company, engages in the development and commercialization of fibroblast-based therapies for patients suffering from chronic diseases.
The company’s product pipeline includes CYWC628 which has completed pre-clinical trial for the treatment of wound healing; CYMS101 which has completed Phase 1 trial for the treatment of multiple sclerosis; CybroCell for the treatment of degenerative disc disease; and CYPS317 for the treatment of psoriasis.
It also develops early-stage research products, including CYTER915 to treat the human longevity; and TCB190 for the treatment of certain cancers.
FibroBiologics, Inc. was incorporated in 2021 and is headquartered in Houston, Texas.